Literature DB >> 17215482

The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction.

Ana C Liberman1, Damian Refojo, Jimena Druker, Marta Toscano, Theo Rein, Florian Holsboer, Eduardo Arzt.   

Abstract

Glucocorticoids (GCs) immunosuppression acts via regulation of several transcription factors (TF), including activating protein (AP)-1, NF-kappaB, and NFAT. GCs inhibit Th1 cytokines and promote a shift toward Th2 differentiation. Th1 phenotype depends on TF T-bet. In this study, we examined GC regulation of T-bet. We found that GCs inhibit T-bet transcriptional activity. We show that glucocorticoid receptor (GR) physically interacts with T-bet both in transfected cell lines and in primary splenocyte cultures with endogenous GR and T-bet. This interaction also blocks GR-dependent transcription. We show both in vitro and in vivo at endogenous binding sites that the mechanism underlying T-bet inhibition further involves reduction of T-bet binding to DNA. Using specific mutations of GR, we demonstrate that the first zinc finger region of GR is required for T-bet inhibition. GCs additionally inhibit T-bet both at mRNA and protein expression levels, revealing another layer of GR action on T-bet. Finally, we examined the functional consequences of GR/T-bet interaction on IFN-gamma, showing that GCs inhibit transcriptional activity of T-bet on its promoter. In view of the crucial role of T-bet in T cell differentiation and inflammation, we propose that GR inhibitory interaction with T-bet may be an important mechanism underlying the immunosuppressive properties of GCs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215482     DOI: 10.1096/fj.06-7452com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  47 in total

Review 1.  Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.

Authors:  Tomomi Toubai; John Magenau
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

Review 2.  Minireview: latest perspectives on antiinflammatory actions of glucocorticoids.

Authors:  Karolien De Bosscher; Guy Haegeman
Journal:  Mol Endocrinol       Date:  2008-12-18

Review 3.  Glucocorticoid receptor: implications for rheumatic diseases.

Authors:  T Kino; E Charmandari; G P Chrousos
Journal:  Clin Exp Rheumatol       Date:  2011-10-21       Impact factor: 4.473

Review 4.  The Interactome of the Glucocorticoid Receptor and Its Influence on the Actions of Glucocorticoids in Combatting Inflammatory and Infectious Diseases.

Authors:  Ioanna Petta; Lien Dejager; Marlies Ballegeer; Sam Lievens; Jan Tavernier; Karolien De Bosscher; Claude Libert
Journal:  Microbiol Mol Biol Rev       Date:  2016-05-11       Impact factor: 11.056

Review 5.  T-bet in disease.

Authors:  Vanja Lazarevic; Laurie H Glimcher
Journal:  Nat Immunol       Date:  2011-06-20       Impact factor: 25.606

Review 6.  Immune regulation by glucocorticoids.

Authors:  Derek W Cain; John A Cidlowski
Journal:  Nat Rev Immunol       Date:  2017-02-13       Impact factor: 53.106

Review 7.  The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease.

Authors:  A Sasha Tait; Cherie L Butts; Esther M Sternberg
Journal:  J Leukoc Biol       Date:  2008-07-29       Impact factor: 4.962

Review 8.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 9.  The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore.

Authors:  John M Busillo; John A Cidlowski
Journal:  Trends Endocrinol Metab       Date:  2013-01-08       Impact factor: 12.015

10.  Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.

Authors:  Herschel Wallen; John A Thompson; J Zachary Reilly; Rebecca M Rodmyre; Jianhong Cao; Cassian Yee
Journal:  PLoS One       Date:  2009-03-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.